🇺🇸 FDA
Pipeline program

Cetuximab

ACCRU-GI-1809

Phase 2 mab active

Quick answer

Cetuximab for BRAF V600E Negative is a Phase 2 program (mab) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
BRAF V600E Negative
Phase
Phase 2
Modality
mab
Status
active

Clinical trials